Faculty Bibliography

PURPOSE: To identify a melanoma microRNA (miRNA) expression signature that is predictive of outcome and then evaluate its potential to improve risk stratification when added to the standard-of-care staging criteria. EXPERIMENTAL DESIGN: Total RNA was extracted from 59 formalin-fixed paraffin-embedded melanoma metastases and hybridized to miRNA arrays containing 911 probes. We then correlated miRNA expression with post-recurrence survival and other clinicopathologic criteria. RESULTS: We identified a signature of 18 miRNAs whose overexpression was significantly correlated with longer survival, defined as more than 18 months post-recurrence survival. Subsequent cross-validation showed that a small subset of these miRNAs can predict post-recurrence survival in metastatic melanoma with an estimated accuracy of 80.2% (95% confidence interval, 79.8-80.6%). In contrast to standard-of-care staging criteria, a six-miRNA signature significantly stratified stage III patients into 'better' and 'worse' prognostic categories, and a multivariate Cox regression analysis revealed the signature to be an independent predictor of survival. Furthermore, we showed that most miRNAs from the signature also showed differential expression between patients with better and worse prognoses in the corresponding paired primary melanoma. CONCLUSIONS: MiRNA signatures have potential as clinically relevant biomarkers of prognosis in metastatic melanoma. Our data suggest that molecularly based models of risk assessment can improve the standard staging criteria and support the incorporation of miRNAs into such models. Clin Cancer Res; 16(5); 1577-86

The central role of Raf protein kinase isoforms in human cancer demands specific anti-Raf therapeutic inhibitors. Parvoviruses are currently used in experimental cancer therapy due to their natural oncotropism and lytic life cycle. In searching for mechanisms underlying parvovirus oncolysis, we found that trimers of the major structural protein (VP) of the parvovirus minute virus of mice (MVM), which have to be imported into the nucleus for capsid assembly, undergo phosphorylation by the Raf-1 kinase. Purified Raf-1 phosphorylated the capsid subunits in vitro to the two-dimensional pattern found in natural MVM infections. VP trimers isolated from mammalian cells translocated into the nucleus of digitonin-permeabilized human cells. In contrast, VP trimers isolated from insect cells, which are devoid of Raf-1, were neither phosphorylated nor imported into the mammalian nucleus. However, the coexpression of a constitutively active Raf-1 kinase in insect cells restored VP trimer phosphorylation and nuclear transport competence. In MVM-infected normal and transformed cells, Raf-1 inhibition resulted in cytoplasmic retention of capsid proteins, preventing their nuclear assembly and progeny virus maturation. The level of Raf-1 activity in cancer cells was consistent with the extent of VP specific phosphorylation and with the permissiveness to MVM infection. Thus, Raf-1 control of nuclear translocation of MVM capsid assembly intermediates provides a novel target for viral oncolysis. MVM may reinforce specific therapies against frequent human cancers with deregulated Raf signaling

Purpose: Stem cell-based therapies aimed at introducing progenitor cells into cartilage lesions hold great promise for the restoration of damaged articular surfaces following joint injury or osteoarthritis. Key to the generation of a functional repair tissue is the controlled differentiation into the desired phenotype. To this end microRNAs (miRNAs) may be important molecules that regulate this process. By acting as transcriptional repressors, their modulation during differentiation may enable commitment to a specific lineage by suppressing the expression of other lineage markers. In this study we profiled MSCs for miRNA expression following induction into the chondrocyte (C), osteoblast (O) and smooth muscle (SM) lineages. Results: Human bone marrow-derived Mesenchymal Stem Cells (MSCs) were obtained from NIH, or from the discarded hips of patients undergoing joint replacement surgery. SM differentiation was induced by treating monolayer cultures with 1 mM thromboxane-A2 [DP1] in the presence of 0.25% serum. C differentiation was induced by seeding MSCs in aggregate cultures in the presence of dexamethasone and TGF-b1 (10 ng/ml). O differentiation was induced by treatment of monolayer cultures with dexamethasone, ascorbate and beta-glycerolphosphate. Profiling of miRNAs by microarray (Agilent) or QPCR (SA Biosciences) revealed differential regulation of miR-7 and miR-130b, among 376 probes. Following SM and C differentiation, miR-7 expression was down-regulated up to 6.9-fold and 3-fold respectively. Conversely, during O differentiation, its expression was induced approximately 7-fold. Analysis of theoretical mRNA targets using TargetScan online software (www.targetscan.org) identified conserved sites in several genes associated with chondrocyte and myoblast lineages. Putative chondrogenic targets were found to include COL2A1, IGFR1, and GDF5, while potential smooth muscle modulators included EGFR1, PIK3CD, IRS1/IRS2, KLF4, CNN3 and IGF1R. Following a similar trend to miR-7, miR-130b was down-regulated up to 3.2-fold and 3.1-fold in C and SM differentiation respectively, while O differentiation induced its expression 2-fold. TargetScan analysis identified putative chondrogenic targets, TGF-BRII, Sox5, BMP-2 and IGF1; Potential smooth muscle regulators included ESR1, TGF-BRII, MBLN1, TGFBR1 and IGF2BP1. Together these observations suggest that miR-7 and miR-130b act to negatively regulate myogenic and chondrogenic cell fates via regulation of lineage specific genes. Conclusion: Our findings suggest that miR-7 and miR-130b, via the targeting of lineage specific molecules, regulate cell fate in adult human MSCs by inhibiting smooth muscle and chondrocyte differentiation, thereby promoting 'default' differentiation into the osteoblast lineage. [DP1]0.25% FBS 24 hours prior to addition of 1.0mM of the TxA2 chemical analog U46619

Overexpression of HMGA2 is common in uterine leiomyomas (ULM). The expression of HMGA2 in its malignant counterpart - uterine leiomyosarcomas (ULMS) remains undetermined. Recently it has been shown that repression of HMGA2 by microRNA let-7s is a critical molecular regulatory mechanism associated with tumour growth in many tumours and cell types, including leiomyomas. To test whether HMGA2 and let-7s play a role in ULMS, we examined the levels of endogenous HMGA2 and let-7 expression and found a significant correlation between these two molecules in a case-matched cohort of human ULMS. We found that overexpression of HMGA2 and let-7-mediated HMGA2 repression is a relevant molecular alteration in ULMS. Disrupting the control of HMGA2 and let-7 pairs promotes ULMS cell growth in vitro

Bladder cancer is one of the most common causes of death in industrialized countries. New tumor markers and therapeutic approaches are still needed to improve the management of bladder cancer patients. Choline kinase-alpha (ChoKalpha) is a metabolic enzyme that has a role in cell proliferation and transformation. Inhibitors of ChoKalpha show antitumoral activity and are expected to be introduced soon in clinical trials. This study aims to assess whether ChoKalpha plays a role in the aggressiveness of bladder tumors and constitutes a new approach for bladder cancer treatment. We show here that ChoKalpha is constitutively altered in human bladder tumor cells. Furthermore, in vivo murine models, including an orthotopic model to mimic as much as possible the physiological conditions, revealed that increased levels of ChoKalpha potentiate both tumor formation (P< or =0.0001) and aggressiveness of the disease on different end points (P=0.011). Accordingly, increased levels of ChoKalpha significantly reduce survival of mice with bladder cancer (P=0.05). Finally, treatment with a ChoKalpha-specific inhibitor resulted in a significant inhibition of tumor growth (P=0.02) and in a relevant increase in survival (P=0.03)

OBJECTIVE: To study whether dysregulation of insulin-like growth factors (IGFs) and IGF signaling are common molecular changes in symptomatic leiomyomas (fibroids) and whether IGFs are associated with large fibroids. DESIGN: Examination of IGFs and IGF pathway genes in a large cohort of fibroids at transcriptional and translational levels. Mechanisms leading to alterations of IGFs and related genes were also analyzed. SETTING: University clinical research laboratory. PATIENT(S): Hysterectomies for symptomatic fibroids were collected: 180 cases from paraffin-embedded tissues and 50 cases from fresh-frozen tissues. INTERVENTION(S): Tissue microarray and immunohistochemistry, DNA methylation analysis, reverse-transcriptase polymerase chain reaction, and Western blot. MAIN OUTCOME MEASUREMENT(S): Transcription and translation analyses of IGF-1/2, p-AKT, p-S6K, and TSC1/2 in fibroids and matched myometrium. RESULT(S): Insulin-like growth factors and downstream effectors were dysregulated in approximately one third of fibroids. All except for IGF-2 seemed to be abnormally regulated at translation levels. Up-regulation of IGF-2 messenger RNAs was contributed by all four alternating slicing promoters. There was a positive correlation of IGF-1 and p-AKT over-expression with fibroid size. Insulin-like growth factor 1 but not IGF-2 levels directly correlated with activation of p-AKT and p-S6K. CONCLUSION(S): Altered expressions of IGFs and their related downstream proteins were found in one third of fibroids. Large fibroids show high levels of IGF-1 and p-AKT activity compared with small ones